The FDA approved Moderna's new mRNA flu vaccine last week. Media praised its higher effectiveness in trials. Yet serious flaws in the trial data from a leading journal drew little notice, raising doubts about the agency's review process.
The FDA gave approval to Moderna's mRNA-based flu vaccine amid much attention on its reported benefits. Coverage in legacy media centered on claims that the shot was over 26 percent more effective than standard flu vaccines at stopping illness. This focus left other key aspects of the trial largely unexamined by the public.
Critics point to problems in the data published in The New England Journal of Medicine. These issues involve how the study measured outcomes and potential gaps in safety reporting. The lack of close inspection suggests the FDA may have overlooked important details during its review.
Such oversights could affect public trust in future vaccine decisions. Experts argue that full transparency on all trial results is needed to ensure vaccines meet high standards. The case highlights the need for balanced reporting beyond just efficacy numbers.
Original Author: Maryanne Demasi | Source: Brownstone Institute
40.308 SRY